Literature DB >> 10213922

Detection of preoperative serum anti-p53 antibodies in gastric cancer.

K Nakajima1, T Suzuki, H Shimada, H Hayashi, A Takeda, T Ochiai.   

Abstract

The presence of circulating anti-p53 antibodies (p53Ab) was investigated in 81 gastric cancer patients by ELISA. Preoperatively, anti-p53Ab were revealed in 13 cases (16%), including 3 early gastric cancers. No significant correlation of p53Ab with patient age, sex, pathological parameters and tumor markers, such as CEA and CA19-9 was observed, although p53Ab positivity tended to be associated with a higher rate of lymph node metastases (p = 0.073). We have found no significant correlation between p53Ab and poor survival rate (p = 0.325). In conclusion, we have observed that p53Ab are detectable in gastric cancer patients, even at early stages of disease, however, p53Ab have not served as a predictor of poor prognosis in gastric cancer in this series.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213922     DOI: 10.1159/000030057

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  10 in total

1.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

2.  Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Koki Kuwabara; Kunihiko Amano; Noriyasu Chika; Norimichi Okada; Tomonori Ohsawa; Youichi Kumagai; Keiichiro Ishibashi
Journal:  Mol Clin Oncol       Date:  2017-08-08

Review 3.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

4.  Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.

Authors:  Kenji Murayama; Tatsuki Nanami; Takashi Suzuki; Yoko Oshima; Satoshi Yajima; Tetsuo Nemoto; Hideaki Shimada
Journal:  Clin J Gastroenterol       Date:  2017-05-24

5.  High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer.

Authors:  Hideaki Shimada; Nobuhiro Takiguchi; Osamu Kainuma; Hiroaki Soda; Atsushi Ikeda; Akihiro Cho; Akinari Miyazaki; Hisashi Gunji; Hiroshi Yamamoto; Matsuo Nagata
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

6.  Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.

Authors:  Hideaki Shimada; Matsuo Nagata; Akihiro Cho; Nobuhiro Takiguchi; Osamu Kainuma; Hiroaki Soda; Atsushi Ikeda; Yoshihiro Nabeya; Satoshi Yajima; Hiroshi Yamamoto; Takahiro Sugiyama; Makiko Itami
Journal:  Surg Today       Date:  2013-11-17       Impact factor: 2.549

7.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

8.  Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.

Authors:  Junko Umeda; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Toshio Kurihara; Takayoshi Tsuchiya; Kentaro Ishii; Shujiro Tsuji; Nobuhito Ikeuchi; Reina Tanaka; Ryosuke Tonozuka; Mitsuyoshi Honjo; Shuntaro Mukai; Toshitaka Nagao; Hisashi Oshiro; Fuminori Moriyasu
Journal:  J Oncol       Date:  2013-12-18       Impact factor: 4.375

Review 9.  p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada
Journal:  Ann Gastroenterol Surg       Date:  2018-06-13

10.  The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers.

Authors:  Meng-Ting Cui; Zhan-Wen Liang; Yi-Zhang Sun; Jing Wu; Hong Lu; Wen-Jie Wang; Meng-Dan Xu; Min Jiang; Wei Li; Jun Qian; Wei-Ming Duan
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.